141 results match your criteria: "Royal Marsden NHS Foundation Trust and The Institute of Cancer Research[Affiliation]"
Clin Oncol (R Coll Radiol)
December 2024
Department of Radiotherapy, The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Sutton, UK. Electronic address:
Aims: The magnitude of upper abdominal organ motion in children may be overestimated by current planning target volumes (PTV). A four-dimensional computed tomography (4DCT) - derived internal target volume (ITV) is frequently used in adult radiotherapy to take respiratory-related organ motion into account. In this study, the dosimetric consequences for target coverage and organs at risk from the use of an ITV approach compared to standard PTV margins in children with high-risk neuroblastoma were investigated.
View Article and Find Full Text PDFSemin Radiat Oncol
October 2024
The Netherlands Cancer Institute, Department of Radiation Oncology, Amsterdam and department of Radiation Oncology, Leiden University Medical Centre the Netherlands, Leiden, The Netherlands.
The implementation and early adoption of online adaptive radiotherapy (oART) has required the presence of clinicians, physicists and radiation therapists (RTT) at the treatment console. The impact on each of them is unique to their profession and must be considered for safe and efficient implementation. In the short term future, widespread adoption will depend on the development of innovative workflows, and rethinking of traditional roles and responsibilities may be required.
View Article and Find Full Text PDFBr J Gen Pract
March 2024
Prostate Cancer UK.
Tech Innov Patient Support Radiat Oncol
June 2024
InHolland Haarlem, University of Applied Science, Haarlem, the Netherlands.
Technological advances in radiation therapy impact on the role and scope of practice of the radiation therapist. The European Society of Radiotherapy and Oncology (ESTRO) recently held two workshops on this topic and this position paper reflects the outcome of this workshop, which included radiation therapists from all global regions. Workflows, quality assurance, research, IGRT and ART as well as clinical decision making are the areas of radiation therapist practice that will be highly influenced by advancing technology in the near future.
View Article and Find Full Text PDFAdv Radiat Oncol
June 2024
The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
Purpose: Swallow-related motion of the larynx is most significant in the cranio-caudal directions and of` short duration. Conventional target definition for radical radiation therapy includes coverage of the whole larynx. This study longitudinally examined respiration- and swallow-related laryngeal motions using cine-magnetic resonance imaging.
View Article and Find Full Text PDFRadiography (Lond)
May 2024
Sheffield Hallam University, Health Research Institute, Sheffield, United Kingdom. Electronic address:
Introduction: The standard toxicity tools adopted for assessing Radiation Induced Skin Reactions (RISR) do not currently reflect how skin changes occur across all skin tones. A one size fits all approach is adopted currently for RISR assessment. The aim of this study was to understand what evidence-based practice and RISR tools are being used across the therapeutic radiography workforce and the levels of confidence in using these tools.
View Article and Find Full Text PDFNeuropathol Appl Neurobiol
April 2024
Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Eye (Lond)
August 2024
Moorfields Eye Hospital NHS Foundation Trust, London, England.
Eye (Lond)
June 2024
Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London, EC1V 2PD, UK.
Objective: To define how estimates of keratoconus progression following collagen cross-linking (CXL) vary according to the parameter selected to measure corneal shape.
Materials And Methods: We estimated progression following CXL in 1677 eyes. We compared standard definitions of keratoconus progression based on published thresholds for Kmax, front K2, or back K2, or progression of any two of these three parameters, with the option of an increased threshold for Kmax values ≥ 55D.
N Engl J Med
January 2024
From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (A.D.) and the NYU Perlmutter Cancer Center (V.V.) - all in New York; the University of Colorado, Anschutz Medical Campus, Aurora (D.R.C.); Massachusetts General Hospital, Harvard Medical School, Boston (J.J.L.); Asan Medical Center (S.-W.K.) and Yonsei Cancer Center, Yonsei University College of Medicine (B.C.C.), Seoul, and Chungbuk National University Hospital, Cheongju-si (K.H.L.) - all in South Korea; the Peter MacCallum Cancer Center, Melbourne, VIC (B.J.S.), and the Chris O'Brien Lifehouse, Camperdown, NSW (S.K.) - both in Australia; the Department of Oncology and Radiotherapy and Early Clinical Trials Center, Medical University of Gdansk, Gdansk, Poland (R.D.); Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif (B.B.), and Centre Hospitalier Universitaire de Grenoble-Alpes, La Tronche (D.M.-S.) - both in France; National Cancer Center Hospital East, Kashiwa, Japan (K.G.); the Netherlands Cancer Institute, Amsterdam (A.J.L.); the Center for Integrated Oncology, University Hospital of Cologne, Cologne (J.W.), and the Department of Medical Oncology, Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg (C.S.) - both in Germany; the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London (S.P.), and the University of Manchester and the Christie NHS Foundation Trust, Manchester (M.G.K.) - all in the United Kingdom; the University of California, Irvine, School of Medicine, Orange (M.N.), and Turning Point Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb, San Diego (S.S., M.M., D.T., A.G., G.S.) - both in California; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (E.F.); Hunan Cancer Hospital, Hunan (N.Y.), the Department of Oncology, Shanghai Chest Hospital, Shanghai (S.L.), Sichuan Cancer Hospital and Institute, Chengdu (W.Y.), and Henan Cancer Hospital, Zhengzhou (X.H.) - all in China; the Respiratory Oncology Unit, University Hospitals Leuven, Leuven, Belgium (C.D.); UT Southwestern Medical Center, Dallas (M.S.B.); William Osler Health System, University of Toronto, Toronto (P.C.); and Bristol Myers Squibb, Princeton, NJ (Y.Y.).
Lancet Oncol
December 2023
Department of Pediatric Oncology, Timone Hospital, AP-HM, Marseille, France; Reverse Molecular Pharmacology in Pediatric Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix-Marseille Université, CNRS, INSERM, Marseille, France; Metronomics Global Health Initiative, Marseille, France.
Ann Oncol
January 2024
Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Background: Checkpoint inhibitor (CPI) therapy revolutionized treatment for advanced non-small-cell lung cancer (NSCLC); however, most patients progress due to primary or acquired resistance. Sitravatinib is a receptor tyrosine kinase inhibitor that can shift the immunosuppressive tumor microenvironment toward an immunostimulatory state. Combining sitravatinib with nivolumab (sitra + nivo) may potentially overcome initial CPI resistance.
View Article and Find Full Text PDFBMJ Open
October 2023
Department of Oncology, Royal Marsden NHS Foundation Trust, London, UK.
Introduction: Patients undergoing prostate radiotherapy with an enlarged prostate can have short-term and long-term urinary complications. Currently, transurethral resection of the prostate (TURP) is the mainstay surgical intervention for men with urinary symptoms due to an enlarged prostate prior to radiotherapy. UroLift (NeoTract, Pleasanton, CA, USA) is a recent minimally invasive alternative, widely used in benign disease but is untested in men with prostate cancer.
View Article and Find Full Text PDFPhys Med
October 2023
Joint Department of Physics, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK. Electronic address:
Purpose: Robustness to residual setup errors and linac delivery errors of BrainLab Elements single-isocentre-multiple-target stereotactic radiosurgery was evaluated.
Methods: Residual setup errors of 13 patients were evaluated. Linac delivery error was quantified through multi-metastases-Winston-Lutz measurements.
Pract Radiat Oncol
March 2024
Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California; Department of Urology, University of California Los Angeles, Los Angeles, California. Electronic address:
Traditionally, external beam radiotherapy (EBRT) for localized prostate cancer (PCa) involved lengthy courses with low daily doses. However, advancements in radiation delivery and a better understanding of prostate radiobiology have enabled the development of shorter courses of EBRT. Ultrahypofractionated radiotherapy, administering doses greater than 5 Gy per fraction, is now considered a standard of care regimen for localized PCa, particularly for intermediate-risk disease.
View Article and Find Full Text PDFNeuro Oncol
December 2023
Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Background: The prognosis for Li-Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data for this patient group is lacking, challenging the development of novel therapeutic strategies. Here, we present clinical and molecular data on a retrospective cohort of pediatric LFS MB patients.
View Article and Find Full Text PDFInvest Radiol
December 2023
From the Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, United Kingdom (A.G.R., X.L., I.L., T.D.B., N.B., G.J.W., N.S., A.L., A.H., E.O.A.); Imaging Department, Imperial College Healthcare NHS Trust, London, United Kingdom (A.G.R., T.D.B., N.B., A.S., J.B., A.F., N.S., K.W., A.L., J.R., M.S.); Imperial Clinical Trials Unit, Imperial College London, London, United Kingdom (N.J., S.S., A.T.P., J.W., X.L.); Centre for Medical Imaging, University College London, London, United Kingdom (S.P., H.S., A.P., S.T.); Department of Radiology, University College London Hospital, London, United Kingdom (S.P., H.S., A.P., S.T.); Cancer Imaging, School of Biomedical Engineering & Imaging Sciences, King's College London and Department of Radiology, Guy's & St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom (V.G., C.K.-M.); Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna General Hospital, Vienna, Austria (G.J.W.); Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom (D.-M.K., C.M., N.T., N.S., C.K.-M., K.N.D.P.); Cancer Research UK and University College London Cancer Trials Unit, London, United Kingdom (K.R.); Faculty of Engineering, Department of Computing, Imperial College London, London, United Kingdom (Q.D., B.G.); King's Cancer Prevention Group, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom (J.W.); Department of Radiology, Homerton NHS Foundation Trust, London, United Kingdom (P.B.); Paul Strickland Scanner Centre, Mount Vernon Hospital (H.S.); Department of Radiology, The Hillingdon Hospitals NHS Foundation Trust, London, United Kingdom (H.S.); Thirlestaine Breast Centre, Gloucestershire Hospitals NHS Foundation Trust, London, United Kingdom (S.V.); and Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's Clinical Trials Unit, London, United Kingdom (A.T.P.).
Objectives: Whole-body magnetic resonance imaging (WB-MRI) has been demonstrated to be efficient and cost-effective for cancer staging. The study aim was to develop a machine learning (ML) algorithm to improve radiologists' sensitivity and specificity for metastasis detection and reduce reading times.
Materials And Methods: A retrospective analysis of 438 prospectively collected WB-MRI scans from multicenter Streamline studies (February 2013-September 2016) was undertaken.
Med Phys
November 2023
Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
Background: T mapping can characterize tumor hypoxia, which may be associated with resistance to therapy. Acquiring T maps during MR-guided radiotherapy could inform treatment adaptation by, for example, escalating the dose to resistant sub-volumes.
Purpose: The purpose of this work is to demonstrate the feasibility of the accelerated T mapping technique using model-based image reconstruction with integrated trajectory auto-correction (TrACR) for MR-guided radiotherapy on an MR-Linear accelerator (MR-Linac).
Int J Radiat Oncol Biol Phys
December 2023
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; London School of Hygiene and Tropical Medicine, London, United Kingdom. Electronic address:
Purpose: Evidence of a volume-outcome association in cancer surgery has shaped the centralization of cancer services; however, it is unknown whether a similar association exists for radiation therapy. The objective of this study was to determine the association between radiation therapy treatment volume and patient outcomes.
Methods And Materials: This systematic review and meta-analysis included studies that compared outcomes of patients who underwent definitive radiation therapy at high-volume radiation therapy facilities (HVRFs) versus low-volume facilities (LVRFs).
Eur J Cancer
July 2023
Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia; School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia; Children's Cancer Institute, University of New South Wales, Sydney, NSW, Australia.
Aim: This phase I/expansion study assessed the safety, pharmacokinetics and preliminary antitumor activity of afatinib in paediatric patients with cancer.
Methods: The dose-finding part enroled patients (2-<18 years) with recurrent/refractory tumours. Patients received 18 or 23 mg/m/d afatinib orally (tablet or solution) in 28-d cycles.
Nat Cancer
April 2023
Oncology Biomarker Development, Genentech, South San Francisco, CA, USA.
We report herein an exploratory biomarker analysis of refractory tumors collected from pediatric patients before atezolizumab therapy (iMATRIX-atezolizumab, NCT02541604 ). Elevated levels of CD8 T cells and PD-L1 were associated with progression-free survival and a diverse baseline infiltrating T-cell receptor repertoire was prognostic. Differential gene expression analysis revealed elevated expression of CALCA (preprocalcitonin) and CCDC183 (highly expressed in testes) in patients who experienced clinical activity, suggesting that tumor neoantigens from these genes may contribute to immune response.
View Article and Find Full Text PDFClin Transl Radiat Oncol
May 2023
The Royal Marsden NHS Foundation Trust, United Kingdom and The Institute of Cancer Research, United Kingdom.
Purpose: A scoping literature review was conducted to identify gastrointestinal (GI) factors most likely to influence prostate motion during radiotherapy. We proffer that patient specific measurement of these GI factors could predict motion uncertainty during radiotherapy, facilitating personalised care by optimising treatment technique e.g.
View Article and Find Full Text PDFEur J Cancer
February 2023
Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
Background: Owing to the rarity and heterogeneity in biology and presentation, there are multiple areas in the diagnosis, treatment and follow-up of soft tissue sarcoma (STS), with no, low-level or conflicting evidence.
Methods: During the first Consensus Conference on the State of Science in Sarcoma (CSSS), we used a modified Delphi process to identify areas of controversy in the field of sarcoma, to name topics with limited evidence-based data in which a scientific and knowledge gap may remain and a consensus statement will help to guide patient management. We determined scientific questions which need to be addressed in the future in order to generate evidence and to inform physicians and caregivers in daily clinical practice in order to improve the outcomes of patients with sarcoma.